Pet GM-CSF Therapeutic Antibody Development

Creative Biolabs is committed to advancing veterinary immunotherapies that address significant unmet medical needs in companion animals. One area of focus is granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine central to inflammation and immune cell activation. Antibody therapeutics targeting GM-CSF are emerging as promising tools for modulating excessive immune responses in dogs and cats. By leveraging state-of-the-art discovery platforms and veterinary-specific expertise, we enable our partners to explore and develop therapeutic antibodies that can transform treatment outcomes. If GM-CSF is on your radar as a therapeutic target, we encourage you to connect with our team to explore tailored solutions.

Platforms in Therapeutic Antibody Discovery

To support the development of GM-CSF–targeted antibodies, Creative Biolabs offers a suite of discovery platforms designed for efficiency and adaptability. Each platform can be tailored to the scope and goals of your program, whether you seek rapid lead generation or detailed antibody optimization.

• Phage Display: We maintain canine- and feline-specific phage display libraries to ensure the discovery of species-compatible antibodies with high binding affinity. This allows us to generate diverse leads against GM-CSF rapidly.
• Single-B Cell Sorting: By isolating antigen-specific murine B cells, we generate natural monoclonals that can undergo optimization for canine or feline application. This approach captures biologically relevant antibodies suitable for downstream engineering.
• Hybridoma Technology: Hybridoma-based discovery remains a robust method for producing monoclonals, particularly when downstream engineering and optimization are required. Our expertise ensures stable clones and consistent antibody output.

Comprehensive Antibody Development Services

We deliver an integrated workflow to move antibody candidates efficiently through the preclinical pipeline.

Antibody Characterization

Detailed binding studies, cross-reactivity assessments, and structural evaluations to confirm therapeutic potential.

Antibody Engineering

Optimization for canine/feline systems, including Fc modification, reduced immunogenicity, and improved half-life.

Preclinical Evaluation

In vitro and in vivo testing to establish efficacy in relevant veterinary disease models, complemented by safety assessments.

Antibody Development

End-to-end support covering lead optimization, manufacturability assessments, and preparation for translational studies.

Discover How We Can Help - Request a Consultation

Why Focus on GM-CSF?

GM-CSF is a cytokine that stimulates the production and activation of granulocytes and macrophages, key players in inflammation. While essential for host defense, dysregulated GM-CSF activity contributes to pathological inflammation. In dogs, GM-CSF has been implicated in immune-mediated polyarthritis, inflammatory bowel disease, and certain dermatological conditions like atopic dermatitis. In cats, aberrant GM-CSF signaling may contribute to chronic inflammatory syndromes and pulmonary immune disorders. By targeting GM-CSF with therapeutic antibodies, it is possible to reduce destructive inflammation while maintaining essential immune functions. This makes GM-CSF a compelling target for both canine- and feline-specific therapeutic innovation.

Mechanism of Action

Anti-GM-CSF antibodies work by binding directly to GM-CSF, preventing it from interacting with its receptor on myeloid cells. This blockade reduces the activation, survival, and proliferation of inflammatory cells such as macrophages, neutrophils, and dendritic cells. As a result, cytokine-driven inflammation is mitigated, alleviating symptoms associated with autoimmune and inflammatory diseases. Importantly, therapeutic antibodies can be engineered to modulate this pathway with high precision, ensuring effective disease control while preserving immune balance in dogs and cats.

Fig 1. Expression of the GM-CSF receptor.¹

Our Advantages

• With platforms tailored to canine and feline systems, we ensure antibody candidates are optimized for species compatibility and clinical relevance.
• Our team integrates discovery, engineering, and evaluation into a seamless workflow, reducing development timelines and risks.
• Clients benefit from both scientific depth and practical execution, making Creative Biolabs a trusted partner for advancing GM-CSF therapeutic antibodies.

Partner with Creative Biolabs

The therapeutic promise of GM-CSF blockade in veterinary medicine is substantial, with opportunities to address chronic inflammatory and autoimmune diseases that impact pet health and quality of life. Creative Biolabs stands ready to support your antibody development programs from discovery through preclinical validation.

Contact us today to discuss your GM-CSF therapeutic antibody development needs and learn how our expertise can help you bring innovative veterinary solutions to market.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Marek, Katarzyna et al. "Functional Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Delivered by Canine Histiocytic Sarcoma Cells Persistently Infected with Engineered Attenuated Canine Distemper Virus." Pathogens (Basel, Switzerland) vol. 12,7 877. 27 Jun. 2023. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/pathogens12070877